POLYMED
POLY MEDICURE LIMITED
Each stock's 10,000-path forecast, rendered as light.
POLY MEDICURE LIMITED (POLYMED) Stock Analysis & Case Study
Is POLYMED a good buy? The data-driven verdict.
POLY MEDICURE LIMITED (POLYMED) trades at ₹1,694,on the numbers it tread carefully, a Downstox Snapshot Score of 33/100.
On the numbers, POLY MEDICURE LIMITED (POLYMED) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 53.6× earnings, ROE of 11.2%, a 54% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
POLYMED fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How POLYMED ranks against the 2,373 companies in our screener
- POLYMED's market cap of 17,168 Cr ranks in the 83rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- POLYMED's book value of ₹306 ranks in the 81st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- POLYMED's promoter holding of 62.4% ranks in the 57th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- POLYMED's 3-year profit (PAT) growth of 24.0% ranks in the 62nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- POLYMED's 3-year revenue growth of 19.0% ranks in the 72nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- POLYMED's debt-to-equity ratio of 0.11x is lower than 75% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is POLYMED overvalued? POLYMED P/E vs peers
POLYMED trades at 53.6× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
POLYMED share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of POLYMED history (21%/yr drift, 44%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| POLYMED 2027 | ₹1,017 | ₹1,785 | ₹3,133 | +5% |
| POLYMED 2028 | ₹851 | ₹1,882 | ₹4,161 | +11% |
| POLYMED 2029 | ₹749 | ₹1,983 | ₹5,249 | +17% |
| POLYMED 2030 | ₹671 | ₹2,090 | ₹6,508 | +23% |
| POLYMED 2031 | ₹618 | ₹2,203 | ₹7,853 | +30% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability POLYMED goes up, or doubles?
The bull case for POLYMED
- POLY MEDICURE LIMITED is part of the nifty200 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹5,249.
The bear case & risks
- POLYMED's P/E of 53.6x is lower than 24% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- POLYMED's return on equity of 11.2% ranks in the 56th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹749.
POLYMED volatility & expected range, how bumpy is the ride?
Over the last 9.8 years POLYMED compounded at 21%/year with annualized volatility of 44%. That volatility implies a 1-year 80% range of ₹1,017-₹3,133, the honest backbone behind any single price target.
POLYMED price forecast, the full 60-month probability fan
POLYMED price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds POLYMED hits common targets within the simulated horizon?
Full multi-horizon detail on the POLYMED price target & forecast page.
POLYMED Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. POLYMED scores 6/8, mixed financial health.
POLYMED MTF margin & leverage across 11 brokers
Margin Trading Facility lets you buy POLYMED with part of the capital. Lower margin % = higher leverage. Rates compared across 11 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.07% | 2.9× |
| Zerodha | 35.02% | 2.9× |
| Groww | 35.24% | 2.8× |
| Dhan | 35.02% | 2.9× |
| Kotak NeoCHEAPEST | 34.97% | 2.9× |
| Paytm Money | 35.40% | 2.8× |
| Pocketful | 35.56% | 2.8× |
| Fyers | 35.71% | 2.8× |
| Anand Rathi | 35.02% | 2.9× |
| Bajaj Broking | 36.00% | 2.8× |
| Share India | 35.20% | 2.8× |
Compare every broker on the POLYMED MTF page.
About POLY MEDICURE LIMITED: sector, index & market-cap context
POLY MEDICURE LIMITED (POLYMED) is a small-cap NSE-listed company, and a constituent of the Nifty 500 index, with a market capitalisation of ₹17,168 Cr. See more stocks on our screener.
How the POLYMED Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of POLY MEDICURE LIMITED's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
POLYMED analysis, FAQs
Is POLY MEDICURE LIMITED (POLYMED) a good buy?
On the numbers, POLY MEDICURE LIMITED (POLYMED) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 53.6× earnings, ROE of 11.2%, a 54% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is POLYMED overvalued or undervalued?
POLYMED trades at 53.6× earnings, expensive versus the ~22× long-run Nifty average.
What is the POLYMED share price target for 2031?
POLYMED's probability-weighted 2031 median target is ₹2,203, with an 80% range of ₹618-₹7,853 (10,000-path Monte-Carlo).
What is the probability POLYMED doubles in 5 years?
The modelled probability of POLYMED reaching ₹3,388 (2×) within 5 years is 33%.
What is the bull case for POLYMED?
POLY MEDICURE LIMITED is part of the nifty200 universe with live, tracked fundamentals on Downstox.
What are the risks in POLYMED?
POLYMED's P/E of 53.6x is lower than 24% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. POLYMED's return on equity of 11.2% ranks in the 56th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.